Beck M - Search Results

1

Successful pregnancy outcome in a patient with Fabry disease receiving enzyme replacement therapy with agalsidase alfa.

Wendt S, Whybra C, Kampmann C, Teichmann E, Beck M. Wendt S, et al. Among authors: beck m. J Inherit Metab Dis. 2005;28(5):787-8. doi: 10.1007/s10545-005-0018-9. J Inherit Metab Dis. 2005. PMID: 16151910

2

Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes.

Whybra C, Kampmann C, Willers I, Davies J, Winchester B, Kriegsmann J, Brühl K, Gal A, Bunge S, Beck M. Whybra C, et al. Among authors: beck m. J Inherit Metab Dis. 2001 Dec;24(7):715-24. doi: 10.1023/a:1012993305223. J Inherit Metab Dis. 2001. PMID: 11804208

3

Electrocardiographic signs of hypertrophy in fabry disease-associated hypertrophic cardiomyopathy.

Kampmann C, Wiethoff CM, Martin C, Wenzel A, Kampmann R, Whybra C, Miebach E, Beck M. Kampmann C, et al. Among authors: beck m. Acta Paediatr Suppl. 2002;91(439):21-7. doi: 10.1111/j.1651-2227.2002.tb03105.x. Acta Paediatr Suppl. 2002. PMID: 12572838

4

Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study.

Baehner F, Kampmann C, Whybra C, Miebach E, Wiethoff CM, Beck M. Baehner F, et al. Among authors: beck m. J Inherit Metab Dis. 2003;26(7):617-27. doi: 10.1023/b:boli.0000005658.14563.77. J Inherit Metab Dis. 2003. PMID: 14707510 Clinical Trial.

5

The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy.

Whybra C, Kampmann C, Krummenauer F, Ries M, Mengel E, Miebach E, Baehner F, Kim K, Bajbouj M, Schwarting A, Gal A, Beck M. Whybra C, et al. Among authors: beck m. Clin Genet. 2004 Apr;65(4):299-307. doi: 10.1111/j.1399-0004.2004.00219.x. Clin Genet. 2004. PMID: 15025723

6

Fabry disease: overall effects of agalsidase alfa treatment.

Beck M, Ricci R, Widmer U, Dehout F, de Lorenzo AG, Kampmann C, Linhart A, Sunder-Plassmann G, Houge G, Ramaswami U, Gal A, Mehta A. Beck M, et al. Eur J Clin Invest. 2004 Dec;34(12):838-44. doi: 10.1111/j.1365-2362.2004.01424.x. Eur J Clin Invest. 2004. PMID: 15606727 Clinical Trial.

7

The right ventricle in Fabry disease.

Kampmann C, Baehner FA, Whybra C, Bajbouj M, Baron K, Knuf M, Wiethoff CM, Trübel H, Beck M. Kampmann C, et al. Among authors: beck m. Acta Paediatr Suppl. 2005 Mar;94(447):15-8; discussion 9-10. doi: 10.1111/j.1651-2227.2005.tb02104.x. Acta Paediatr Suppl. 2005. PMID: 15895706

8

Cumulative incidence rates of the mucopolysaccharidoses in Germany.

Baehner F, Schmiedeskamp C, Krummenauer F, Miebach E, Bajbouj M, Whybra C, Kohlschütter A, Kampmann C, Beck M. Baehner F, et al. Among authors: beck m. J Inherit Metab Dis. 2005;28(6):1011-7. doi: 10.1007/s10545-005-0112-z. J Inherit Metab Dis. 2005. PMID: 16435194

9

Association between polymorphisms of endothelial nitric oxide synthase gene (NOS3) and left posterior wall thickness (LPWT) of the heart in Fabry disease.

Rohard I, Schaefer E, Kampmann C, Beck M, Gal A. Rohard I, et al. Among authors: beck m. J Inherit Metab Dis. 2008 Dec;31 Suppl 2:S349-56. doi: 10.1007/s10545-008-0920-z. Epub 2008 Oct 22. J Inherit Metab Dis. 2008. PMID: 18941922

10

Angiokeratoma and pain, but not Fabry's disease: considerations for differential diagnosis.

Ries M, Wendrich K, Whybra C, Kampmann C, Gal A, Beck M. Ries M, et al. Among authors: beck m. Contrib Nephrol. 2001;(136):256-9. doi: 10.1159/000060198. Contrib Nephrol. 2001. PMID: 11688390 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,387 results

Search Page